| Thrombolysis of occluded infrainguinal vein grafts: predictors of outcome. | |
| | |
MedLine Citation:
|
PMID: 9201163 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The purpose of this study was to identify factors that influence graft patency and limb salvage rates after thrombolysis of occluded infrainguinal vein grafts. METHODS: The records of patients who underwent percutaneous catheter-directed thrombolysis of occluded infrainguinal vein bypass grafts at our institution between 1985 and 1995 were reviewed. Life table analysis was used to determine survival and patency differences. Univariate and multivariate analyses were used to identify the patient-specific factors that affected outcomes. RESULTS: Forty-four patients with 44 thrombosed infrainguinal vein grafts underwent thrombolysis with urokinase. The thrombolysis-related mortality rate was 2%, and nonfatal complications occurred in 16%. Thrombolysis was unable to restore graft patency in 25% of grafts (11 of 44). Of the remaining 33 successfully lysed grafts, 88% required adjunctive surgery or percutaneous transluminal angioplasty after thrombolysis. Overall, the primary graft patency rate was 25% at 1 year and 19% at 2 years after thrombolysis. Considering only successfully lysed grafts, the primary patency rate improved to 34% at 1 year and 25% at 2 years. Multivariate analysis revealed that the graft patency rate was substantially better in patients without diabetes and in vein grafts that had been in place for longer than 12 months (p < 0.01). The limb salvage rate was significantly improved by successful thrombolysis (63% at 2 years vs 31% if lysis failed; p < 0.01). The patient survival rate was high-89% 2 years after thrombolysis. CONCLUSIONS: Even with adjunctive therapy, vein graft thrombolysis is unlikely to yield durable patency overall. However, successful thrombolysis improves limb salvage rates and may be beneficial in patients without diabetes who have mature vein grafts but who do not have options for other autogenous revascularization procedures. |
| | |
Authors:
|
G B Nackman; D B Walsh; M F Fillinger; R M Zwolak; F R Bech; M A Bettmann; J L Cronenwett |
Related Documents
:
|
12663983 - Brachiobasilic arteriovenous fistula: different surgical techniques and their effects o... 1433663 - Reconstruction of large veins for nonmalignant venous occlusive disease. 1692753 - Local microwave hyperthermia in the treatment of benign prostatic hypertrophy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of vascular surgery Volume: 25 ISSN: 0741-5214 ISO Abbreviation: J. Vasc. Surg. Publication Date: 1997 Jun |
Date Detail:
|
Created Date: 1997-07-17 Completed Date: 1997-07-17 Revised Date: 2012-10-03 |
Medline Journal Info:
|
Nlm Unique ID: 8407742 Medline TA: J Vasc Surg Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1023-31; discussion 1031-2 Citation Subset: IM |
Affiliation:
|
Section of Vascular Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Diabetic Angiopathies / drug therapy, mortality Female Graft Occlusion, Vascular / drug therapy*, mortality Humans Leg / blood supply* Life Tables Male Plasminogen Activators / therapeutic use* Proportional Hazards Models Survival Rate Thrombolytic Therapy* Treatment Outcome Urokinase-Type Plasminogen Activator / therapeutic use* Vascular Patency Veins / surgery |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.73/Urokinase-Type Plasminogen Activator |
| Comments/Corrections | |
Comment In:
|
J Vasc Surg. 1998 Jan;27(1):192-3
[PMID:
9474103
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemodynamic impact of vein graft stenoses and their prediction in the vascular laboratory.
Next Document: Validation of a new and specific intraoperative measurement of vein graft resistance.